

# What happens after they survive? The role of anticoagulants and antiplatelets in IVC injuries

Allyson M Hynes ,<sup>1,2</sup> Dane R Scantling,<sup>3</sup> Shyam Murali,<sup>4</sup> Bradford C Bormann,<sup>5</sup> Jasmeet S Paul,<sup>2</sup> Patrick M Reilly,<sup>4</sup> Mark J Seamon,<sup>4</sup> Niels D Martin<sup>4</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/tsaco-2022-000923>).

<sup>1</sup>Emergency Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA

<sup>2</sup>Surgery, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA

<sup>3</sup>Surgery, Boston University School of Medicine, Boston, Massachusetts, USA

<sup>4</sup>Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA

<sup>5</sup>Surgery, Christiana Care Health Services, Wilmington, Delaware, USA

## Correspondence to

Dr Allyson M Hynes; [AHynes@salud.unm.edu](mailto:AHynes@salud.unm.edu)

Received 15 March 2022

Accepted 20 May 2022

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Hynes AM, Scantling DR, Murali S, et al. *Trauma Surg Acute Care Open* 2022;**7**:e000923.

## ABSTRACT

**Background** Venous thromboembolism (VTE) after an inferior vena cava (IVC) injury is a devastating complication. Current practice involves variable use of anticoagulation and antiplatelet (AC/AP) agents. We hypothesized that AC/AP can reduce the incidence of VTE and that delayed institution of AC/AP is associated with increased VTE events.

**Methods** We retrospectively reviewed IVC injuries cared for at a large urban adult academic level 1 trauma center between January 1, 2008 and December 31, 2020, surviving 72 hours. Patient demographics, injury mechanism, surgical repair, type and timing of AC, and type and timing of VTE events were characterized. Postoperative AC status during hospital course before an acute VTE event was delineated by grouping patients into four categories: full, prophylactic, prophylactic with concomitant AP, and none. The primary outcome was the incidence of an acute VTE event. IVC ligation was excluded from analysis.

**Results** Of the 76 patients sustaining an IVC injury, 26 were included. The incidence of a new deep vein thrombosis distal to the IVC injury and a new pulmonary embolism was 31% and 15%, respectively. The median onset of VTE was 5 days (IQR 1–11). Four received full AC, 10 received prophylactic AC with concomitant AP, 8 received prophylactic AC, and 4 received no AC/AP. New VTE events occurred in 0.0% of full, in 30.0% of prophylactic with concomitant AP, in 50.0% of prophylactic, and in 50.0% without AC/AP. There was no difference in baseline demographics, injury mechanisms, surgical interventions, and bleeding complications.

**Discussion** This is the first study to suggest that delay and degree of antithrombotic initiation in an IVC-injured patient may be associated with an increase in VTE events. Consideration of therapy initiation should be performed on hemostatic stabilization. Future studies are necessary to characterize the optimal dosing and temporal timing of these therapies.

**Level of evidence** Therapeutic, level 3.

## BACKGROUND

Inferior vena cava (IVC) injuries, inclusive of various types, locations, and severities, account for up to 40% of major abdominal vascular injuries and carry a mortality rate of 20% to 66%.<sup>1–10</sup> Following injury, surgical exploration and repair can be arduous and inclusive of high-volume bleeding and major risk of death. Patients surviving IVC injury are at high risk of catastrophic complications, including major life-threatening bleeding, IVC thrombosis, deep vein thrombosis (DVT), and pulmonary embolus

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Traumatic injury lends an individual susceptible to venous thromboembolism (VTE) events.
- ⇒ Within injured patients, several cohorts exist that have a higher incidence of VTE, including patients with an injured inferior vena cava.

## WHAT THIS STUDY ADDS

- ⇒ This study provides stratification to thromboprophylaxis regimens and suggests that more aggressive prophylaxis can mitigate VTE events.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE AND/OR POLICY

- ⇒ On hemostatic stabilization, a clinician should consider initiating appropriately aggressive antithrombotic medications.

(PE).<sup>4–8–11</sup> The incidence of venous thromboembolism (VTE) has been reported to be 1.1% to 18.9% in DVT and 0.4% to 4.6% in PE.<sup>8–9–11</sup>

Best practices for antithrombotic prophylaxis in patients with traumatic vascular injury remain unclear, as demonstrated by the American Association for the Surgery of Trauma in the multicenter PROOVIT (PROspective Observational Vascular Injury Trial), which found no consistent approach to anticoagulation across 542 patients with various vascular injuries.<sup>12</sup> Surgical repair of the IVC further disrupts the endothelium and may also introduce luminal stenosis, both of which further increase the risk of VTE. In addition, a focal hematoma can compress the vessel, disrupting laminar flow.

This risk, however, must be balanced by acute bleeding concerns after an extensive retroperitoneal dissection needed for surgical repair,<sup>13</sup> which can lend a risk of excess bleeding in addition to other concomitant injuries that may continue to bleed (ie, liver laceration, splenic laceration). Additionally, the plausibility of incomplete hemostasis, missed injuries, or iatrogenic injuries must be considered before instituting these modalities. Lastly, if the patient had other injuries that contaminated the repair including enteric contents, fecal contents, or pancreatic enzymes, then there is always the possibility of dehiscing the IVC suture line. This then renders a high-flow, low-pressure catastrophic bleed.

Antithrombotic agents are widely used postoperatively and even beyond hospital discharge to mitigate VTE events, but for patients with IVC injuries specifically no studies have conclusively

**Table 1** Baseline demographic comparison of the AC and AP cohorts

	Entire cohort (N=26)	Full (n=4)	Prophylactic+AP (n=10)	Prophylactic (n=8)	None (n=4)
Demographics and clinical variables					
Age (years)	26 (16–51)	24 (22–26)	25 (16–57)	29 (20–51)	24 (16–28)
Male (%)	26 (100)	4 (100)	10 (100)	8 (100)	4 (100)
BMI (kg/m <sup>2</sup> )	24.4 (19.7–45.6)	24.4 (19.9–30.9)	26.3 (19.7–45.6)	22.3 (18.9–47.0)	24.4 (23.6–28.1)
Penetrating (%)	24 (92)	4 (100)	9 (90)	9 (100)	3 (75)
ISS	22 (9–38)	21 (10–34)	22 (9–34)	18 (9–38)	27 (9–43)
AIS score of abdomen	4 (3–5)	4 (3–5)	4 (3–5)	4 (3–5)	3 (3–4)
Trauma exsanguination protocol (%)	17 (71), n=24	3 (75)	6 (67), n=9	5 (71), n=7	3 (75)
Operative management					
Surgical intervention (%)	24 (92)	4 (100)	9 (90)	9 (100)*	3 (75)
Postoperative outcomes					
IVC filter (%)	5 (19)	0 (0)	2 (20)	2 (22)	1 (25)
Mortality (%)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

All values are n (%) or median (IQR).  
 There was no significant difference between the treatment groups with regard to baseline demographics.  
 \*One patient required surgical intervention, but the retroperitoneum was not explored.  
 AC, anticoagulation; AIS, Abbreviated Injury Scale; AP, antiplatelet; BMI, body mass index; ISS, Injury Severity Score; IVC, inferior vena cava.

demonstrated an ideal course for treatment.<sup>12</sup> Herein, this study sought to evaluate the relationship between various antithrombotic regimens with the incidence of acute VTE in patients with an IVC injury. We conducted a retrospective clinical study in which our hypothesis was that varied anticoagulant and antiplatelet dose regimens exist, and these regimens will result in a varied incidence of acute VTE events after IVC injury. Such study is necessary as potentially preventable deaths could then be mitigated.

## METHODS

### Patients and data collection

We performed a retrospective observational study at our large, urban, academic, medical center and level 1 trauma center between January 1, 2008 and December 31, 2020. Data were curated from our institutional trauma registry and electronic medical record (EMR). The registry was queried for all patients who sustained a traumatic IVC injury requiring hospital admission. On EMR review, patients who were ultimately found not to have sustained an IVC injury or if they died within the index 72 hours were excluded from analysis. An investigation of cause of death was performed on patients who survived beyond their index operation; however, succumbed to death within the first 72 hours. Furthermore, due to the inherent differences in underline presenting physiology, a patient was excluded from the VTE analysis if they underwent an IVC ligation (online supplemental figure 1).

We classified patients into four cohorts: full-dose anticoagulation, prophylactic dose anticoagulation, prophylactic dose anticoagulation with concomitant antiplatelet agent, and no anticoagulant or antiplatelet agent. During the study period, standard-of-care prophylaxis was based on empiric dosing and not titrated to any measure. Patients were assigned to their cohort depending on their current treatment before an acute VTE event or hospital discharge, whichever occurred first. Therefore, if a patient received full-dose anticoagulation, but they were transitioned to prophylactic anticoagulation before sustaining an acute VTE, then the patient was analyzed in the prophylactic dose regimen. Pre-existing home medications were characterized. Our analysis included any available EMR data up to 6 months postacute hospitalization discharge.

Our primary outcome was the incidence of an acute VTE event. An acute VTE included IVC thrombus (presumed at the site of injury), any DVT distal to the IVC injury (ie, ileac veins), or PE. Only a patient's first acute VTE event was recorded in the analysis for time to VTE event. If a patient sustained both a DVT and a PE, this was also characterized.

Descriptive variables included patient demographics (age, gender, body mass index), injury mechanism and details (mechanism, Injury Severity Score, Abbreviated Injury Scale score of the abdomen, trauma exsanguination protocol activation), surgical methods (type of operation, IVC filter placement), type and timing of all antithrombotic agents (including discharge regimens), timing of VTE events, and outcomes (mortality, bleeding complications, new VTE events after hospital discharge).

Although this is an observational study, it should be noted that during the investigation period our DVT surveillance protocol underwent several modifications, which may have affected our recorded incidence of DVT detection. Briefly, in the first 4 years of the study period, screening was optional in the high-risk and very high-risk patients; however, it became mandatory for this cohort in 2012. Then, in 2017, screening again de-escalated. When performed, asymptomatic screening typically involved duplex ultrasound imaging of the lower extremities, usually performed within the first 5 days of admission and continued every 5 to 7 days up to either 3 weeks or until three negative duplexes (online supplemental table 1). In addition, imaging was also obtained when clinical suspicion arose, at the provider's discretion. Article preparation was guided by STROBE (Strengthening The Reporting of OBServational Studies in Epidemiology; checklist provided in online supplemental materials).

## RESULTS

Of the 84 patients screened from the registry query, 76 sustained an IVC injury on EMR review. 26 met all the inclusion and exclusion criteria. On EMR review, 8 were excluded as they did not have an IVC injury, 23 died in the emergency department, 22 died in the operating room, and 4 died within the index 72 hours (online supplemental figure 1). In addition, one patient underwent an IVC ligation.

Four patients were partitioned into the therapeutic dose anticoagulation. Ten patients received concomitant prophylactic

**Table 2** Description of patient injuries, including a description of the IVC injury

Patient	Injury burden	IVC injury description
1	Right colectomy, mesenteric injury, SBR, embolization of the proximal SMA and ileocolic artery.	Suture line on the right lateral wall of the infrarenal IVC performed at OSH.
2	Aorta-caval fistula (stent), Gr 5 renal (nephrectomy), Gr 3 D2 injury ×2, SBR.	Nickel-size anterior hole extending inferior toward the renal hilum; 3–0 Prolene running.
3	Gr 3 D3 ×2 (primary), Gr 2 gastric greater curve (primary), G1 colon (right hemicolectomy), frx: L4.	1 cm anterior and 1 cm posterior infrarenal injury; 4–0 Prolene running.
4	SBR ×2, ileocolic mesenteric injury ×5, ilium frx.	2 cm proximal to the iliac confluence; single 5–0 Prolene figure 8.
5	Gr 4 liver, Gr 2 right renal, Gr 3 left renal, HTX, frx: L2 TP, olecranon, alar.	2 cm lateral longitudinal near renal vein; 4–0 Prolene running and 2 figure 8 reinforcement.
6	Renal laceration, lumbar artery coil, PSA a embolize, PPTX, and contusion, frx: 4/5 rib, clavicle, L2–L4 TP, Le Fort 3, bilateral upper extremities	IVC not repaired.
7	Small bowel injury ×4 (SBR ×2), frx: humerus.	Infrarenal anterior longitudinal 2.5 cm and lateral 1.5 cm; 4–0 running <10% diameter loss.
8	4 cm transverse D1 and 2 cm anterior D2 (both primarily), pancreas (drain), liver, renal hematoma.	2–3 cm longitudinal anterior infrarenal injury; 3–0 running Prolene slight narrowing.
9	Liver, superior/lateral pancreas, duodenal ×2 (primary), pyloric exclusion, cholecystectomy, mid-jejunum (SBR multiple), right colon (colostomy), frx: L1/L2 (incomplete paraplegia), ulnar/radial, iliac.	Infrarenal injuries (×3): posterior injury longitudinal and linear, lateral injury, anterior injury that was extended; 4–0 Prolene.
10	Pancreas (drained), posterior duodenum (primarily) right hemicolectomy (mesenteric hematoma).	2 cm lateral; 4–0 Prolene interrupted, then second layer of 4–0 Prolene running.
11	Liver (segments 4 and 5), pancreas (uncinate), CBD (T-tube), colon (right hemicolectomy), frx: femur, L3.	3 cm defect anteromedially; 5–0 Prolene with significant stenosis.
12	D3 ×2 (primary), SBR (multiple), mesenteric injury.	Infrarenal extends to the iliac; running Prolene, reinforced with interrupted.
13	Gr 1 spleen, Gr 1 liver, right pulmonary contusion.	IVC not repaired.
14	3 liver lacerations, branch of right hepatic artery (requiring IR embolization).	2 mm anterior injury at the renal hilum junction; 4–0 Prolene figure 8.
15	Aorta-caval fistula (repair, stent, repair), D2 ×2 (primary), PTX.	Infrahepatic requiring venopulmonary artery bypass; 2 4–0 Prolene with pledgets.
16	Liver, gastric (greater curve, posterior) (primary), pancreatic head (drained), cholecystectomy, L3 partial hemiplegia.	Anterior and inferior posterior injury; 5–0 Prolene longitudinally, lost two-thirds diameter.
17	Gastric ×2 (gastric wedge, ultimately gastrojejunostomy and pyloric exclusion), duodenum ×2 (initially primary repair), transverse colon resection, Gr 1 liver, L3 (unstable).	3 cm medial injury few centimeters inferior to the renal vein involving 50% circumference; 3–0 Prolene running with narrowing that was unavoidable.
18	Cecal and TI injury resulting in completion right hemicolectomy with right ileocolonic anastomosis.	Infrarenal lateral and posterior injuries; 3–0 Prolene whip stitch.
19	Gr 3 liver, transected gallbladder (cholecystectomy), 2 cm lateral D2 (primary), Gr 1 bilateral kidney.	Infrahepatic 1.5 cm anterior; 4–0 running Prolene with 5–0 interrupted Prolene.
20	Small bowel (SBR), mesenteric injury, transected ureter (PCN).	Infrarenal 3 cm anterior injury; double running with 40% loss in diameter.
21	Gr 3 D3 and D4 anterior and posterior duodenal (primary), renal pseudoaneurysm ×2 IR, mesenteric.	Infrarenal right side 7 o'clock 1 cm and left side 3 o'clock 2 cm, double venorrhaphy.
22	Gr 5 pancreas and distal pancreas (drains/stent), partial hepatectomy, cholecystectomy, severed GDA, transect renal artery and vein.	4 cm medial suprarenal with possible renal artery; 4–0 Prolene running without narrowing.
23	Small bowel injury (SBR), renal hematoma, L4/L5 (ASIA-B), right 12th rib.	IVC not repaired.
24	Liver, portal vein, pancreatic neck (distal pancreatectomy), splenectomy, nephrectomy, lumbar artery embolize, frx: L2/L3 TP, tibia/fibula, iliac wing.	Juxtarenal; 3–0 Prolene running without narrowing.
25	Nephrectomy, pancreas head (drain), colon splenic flexure (ostomy), adrenal, lumbar artery, frx: femur, tibia.	Infrarenal lateral through and through; 4–0 Prolene with some narrowing.
26	85% infrarenal aortic (shunt/repair), jejunum (SBR), right tibial/peroneal artery, iliac wing frx.	Lateral infrarenal hole; running Prolene.

ASIA, American Spinal Injury Association; BLUE, bilateral upper extremities; CBD, common bile duct; chole, cholecystectomy; D, duodenum; frx, fracture; GDA, gastroduodenal artery; Gr, grade; HTX, hemithorax; IR, interventional radiology; IVC, inferior vena cava; OSH, outside hospital; PCN, percutaneous nephrostomy; PSA, posterior superior alveolar; PTX, pneumothorax; SBR, small bowel resection; SMA, superior mesenteric artery; TI, terminal ileum; TP, transverse process.

dose anticoagulation with an antiplatelet agent. Eight patients received prophylactic dose anticoagulation. Four patients did not receive any anticoagulation or antiplatelet agents. Of the fully anticoagulated patients, two received a concomitant antiplatelet agent during part of their hospital course.

Overall, 26 (100.0%) were male and the median age was 26 (IQR 16–51). Of the patients, 24 (92.3%) sustained a penetrating injury and 22 (84.6%) sustained a gunshot wound. The descriptors of their injury burden and operative details are listed in [table 1](#), including 24 (92.3%) who went to the operating theater. These 26 patients were admitted by 18 different trauma attendings. [Table 2](#) depicts patients' injuries, including their cava injuries.

None of the patients were noted to be on an anticoagulant as a home medication; however, one patient in the prophylactic anticoagulation with a concomitant antiplatelet agent was noted to have aspirin and effient as home medications. Four (15.4%) of the patients had data missing on their home medications.

However, none of these four patients had a pre-existing condition warranting an antithrombotic agent.

Nine (34.6%) acute VTE events were reported. Four PEs and eight DVTs occurred in nine different patients and the anatomic locations of the DVTs are described in [table 3](#). New VTE events occurred in zero (0.0%) patient in the full-dose cohort, in three (30.0%) patients in the prophylactic dose with concomitant antiplatelet agent cohort, in four (50.0%) patients in the prophylactic cohort, and in two (50.0%) patients without antithrombotic agents ([figure 1](#)). Of note, three IVCs were thrombosed, two prophylactic patients and one patient without any antithrombotic agents. Additionally, one prophylactic patient whose IVC was stenosed sustained a right femoral DVT.

[Table 4](#) depicts the antithrombotic regimen throughout the hospital course, including changes to the daily antithrombotic medications along with hospital days of VTE events. Notably, one patient who was classified in the category without receiving antithrombotic agents had been on prophylactic dose

**Table 3** Location of deep vein thrombosis

Patient	HD-DVT	Location of DVT
17	1-DVT	IVC thrombosis.
19	5-DVT	Soleal DVT that propagated on serial ultrasounds into the peroneal vein and posterior tibial vein meeting full-dose AC criteria.
20	5-DVT	IVC stenosis (50%) with right femoral DVT.
22	11-DVT	Right popliteal DVT with partial mobile tip.
23	7-DVT	IVC thrombosis with occlusive iliac veins. Right profunda DVT and left soleal DVT. IVC/iliac vein recanalization recommended.
24	3-DVT	IVC thrombosis and left popliteal vein thrombosis.
25	10-DVT	Left iliac vein thrombosis extending toward the IVC and the left femoral vein.
26	19-DVT	PE diagnosed during admission (HD 11) on AC, probable right external iliac DVT by CT. Workup would not change management.

AC, anticoagulation; DVT, deep vein thrombosis; HD, hospital day; IVC, inferior vena cava; PE, pulmonary embolism.

anticoagulation from hospital days 3 to 8, then was transitioned to full-dose anticoagulation on day 8. On hospital day 10, the full-dose and prophylactic dose anticoagulation were discontinued due to a gastrointestinal bleed. The patient was then diagnosed with a pulmonary embolism on day 11 in addition to a DVT on day 19. They received an IVC filter on hospital day 11 and their full-dose anticoagulation resumed on hospital day 14. Of the four fully anticoagulated patients, none sustained an acute bleeding complication after full-dose anticoagulation initiation. Online supplemental table 2 provides a detailed account of the bleeding events.

The median days to onset of an acute VTE event was 5 (IQR 1–11). The hospital days that the four cohorts sustained an acute VTE event with their respective median time to receiving anticoagulation and antiplatelet treatment modalities are included in table 5. Notably, the timing only depicts current antithrombotic initiation that the patient is on immediately before a VTE event. All patients who sustained an acute VTE event had undergone primary repair, except for one patient who did not undergo an operation. It should be noted that the incidence of DVT detection increased over time; conversely, the DVT screening process became less aggressive over time.

Online supplemental table 3 depicts patients' discharge regimens after hospitalization. Most of the patients maintained their hospital regimen. Of note, one patient who was in the prophylactic anticoagulation category sustained a new VTE after discharge. Furthermore, on posthospitalization follow-up, there were expected VTE propagations of previously diagnosed DVTs. Two out of the three IVC that were thrombosed had further

propagation distally on outpatient follow-up. Finally, one patient (3.8%) did not complete posthospitalization follow-up.


Of the four patients who died within the index 72 hours, one died immediately after their operation and the remainder had a re-exploratory laparotomy confirming coagulopathy as the cause of their death.

## DISCUSSION

Traumatically injured patients often have risk factors that lend them to be hypercoagulable, rendering them susceptible to VTE events.<sup>14 15</sup> In this retrospective study of IVC-injured patients, we sought to determine the association between anticoagulation/antiplatelet status and the incidence of acute VTE events. Our results show this group to be very high risk, with a 50.0% acute VTE event rate in patients with prophylactic dose anticoagulation and in patients who were not receiving an antithrombotic agent. On the other hand, those receiving full-dose anticoagulation had a 0.0% acute VTE event rate. These novel and striking findings should prompt consideration of more aggressive anticoagulation/antiplatelet treatment therapies in this high-risk population.

The increased VTE event rate in patients with IVC injuries is thought to occur due to disturbance in the laminar flow through endothelial layer disruption and/or the disruption caused by an outflow obstruction when the repair becomes stenosed.<sup>16–19</sup> To capture this pathology, we excluded all deaths within the first 72 hours. Of the 49 excluded patients, 48 died within the first 24 hours and the 49th patient died within the first 48 hours. Excluding these patients ensured that we were more likely to include patients who sustained an acute VTE event as the result of disruption of the laminar flow and less likely to include patients who had a non-survivable injury without enough time to contract an acute VTE.

Our 34.6% incidence of acute VTE events is compatible with the existing body of literature.<sup>14 20–28</sup> In a large prospective study of 716 patients, it was found that traumatically injured patients have a high incidence of VTE events, with up to 57.6% incidence in those without prophylactic anticoagulation.<sup>14</sup> Our cohort of four patients who did not have prophylactic anticoagulation had an incidence of DVT distal to the IVC injury of 50.0%. Prior literature has suggested that there may be a synergistic effect when antiplatelet agents are combined with pharmacological prophylactically dosed anticoagulants and our findings noted an improvement in the VTE event from 50% to 30% when an antiplatelet agent was added to the prophylactic regimen.<sup>29</sup> These findings are strikingly different from those who received full-dose anticoagulation, as our incidence of VTE events in this cohort was 0.0%. The literature on the incidence of acute VTE



**Figure 1** Bar graph with anticoagulation and antiplatelet (AP) as the independent variable and the incidence of acute venous thromboembolism events as the dependent variable.

**Table 4** Temporal timing of antithrombotics and venous thromboembolic events by patient

Patient	VTE	Timing of antithrombotic and venous thromboembolic events
<b>Full</b>		
3	N/A	HD 1 PPX enox, HD1–5 FD hep (HD 6–10 ASA 325), HD 5–10 PPX enox, 10–12 and 14–16 FD hep (HD 12–14 FD enox), HD 16–20 FD apix; LOS 20 days
5	N/A	HD 2–4 PPX hep (HD 2–5 ASA), HD 4–6 FD hep, 7–9 FD enox, 10–16 FD dabigatran; LOS 16 days
14	N/A	HD 4–8 PPX hep, HD 12–19 FD hep; LOS 19 days
18	N/A	HD 3–4 PPX hep, HD 4–5 FD warfarin, HD 6–11 FD enox; LOS 11 days
<b>Prophylactic with concomitant antiplatelet</b>		
1	N/A	HD 9–44 PPX hep (HD 15–35 ASA), HD 44–46 FD hep (our HD 9), HD 52–71 PPX enox (HD 55–71 ASA), HD 1 IVC-F; LOS 71 days
6	N/A	HD 3–20 PPX enox with ASA; LOS 20 days
7	N/A	HD 1–7 PPX enox with ASA; LOS 7 days
10	N/A	HD 4–26 PPX dalteparin (HD 4–26 ASA 325); LOS 26 days
11	N/A	HD 4–12 FD hep, HD 24–54 PPX dalteparin (HD18–54 ASA 325); LOS 54 days
12	N/A	HD 3–8 PPX dalteparin (HD 4–6 ASA suppository, HD 7–8 ASA 325); LOS 8 days
16	N/A	HD 3–18 PPX hep (HD 17–18 ASA 325); LOS 18 days
21	4 PE	HD 2–4 PPX enox (HD 2–4 ASA suppository), HD 4–20 FD enox (HD 4–23 ASA 325), HD 20–23 FD apix; LOS 23 days
22	11 DVT	HD 2–19 PPX hep (HD 3–25 ASA 81), HD 19–33 FD hep, HD 34–44 PPX hep, HD 44–46 PPX enox, HD 12 IVC-F; LOS 59
25	10 DVT	HD 3–7 PPX hep (HD 4–51 ASA 81), HD 8–11 PPX dalteparin, HD 11–51 FD dalteparin, HD 31–51 warfarin (took a while for INR to become therapeutic); LOS 51 days
<b>Prophylactic anticoagulation</b>		
2	N/A	HD 2–48 PPX hep (HD 6–10 ASA), HD 48–58 PPX enox; LOS 58 days
4	N/A	HD 0–6 PPX enox; LOS 6 days
8	N/A	HD 3–9 PPX enox; LOS 9 days
9	N/A	HD 1–125 PPX hep (HD 3–22 ASA suppository); LOS 125 days
19	5 DVT, 23 PE	HD 3–5 PPX enox, HD 5–11 PPX hep (HD 7–9 ASA suppository, HD 10–28 ASA 325), HD 12–28 PPX enox, HD 29 FD hep, HD 30–77 FD enox; LOS 77
20	5 DVT	HD 2–5 PPX hep, HD 5–9 FD hep, HD 9–10 PPX hep, HD 10 IVC-F; LOS 17
23	7 DVT, 8 PE	HD 3–4 PPX hep, HD 4–8 PPX enox, HD 8–9 FD hep, HD 9–34 FD enox, HD 32–34 warfarin, HD 9 IVC-F; LOS 34 days
24	3 DVT	HD 2–3 PPX hep, HD 3–36 FD hep, HD 34–44 warfarin; LOS 44 days
<b>No antithrombotics</b>		
13	N/A	No antithrombotics; LOS 3
15	N/A	No antithrombotics; LOS 41 days
17	1 DVT	HD 3–4 PPX hep, HD 4–24 FD hep, HD 24–30 FD enox, HD 30–37 FD hep, HD 38–54 FD enox, HD 54 dalteparin; LOS 54 days
26	11 PE, 19 DVT	HD 3–8 PPX hep, HD 8–10 FD hep, HD 14–29 FD hep, HD 11 IVC-F; LOS 34 days

apix, apixaban; ASA, aspirin; DVT, deep vein thrombosis; enox, enoxaparin; FD, full dose; HD, hospital day; hep, heparin; INR, international normalized ratio; IVC-F, inferior vena cava filter; LOS, length of stay; N/A, not applicable; PE, pulmonary embolism; PPX, prophylactic dose; VTE, venous thromboembolism.

events has widely variable data, with an incidence as high as 57.6% in the general trauma population and an incidence as low as 1.2% in the traumatic IVC injury population.<sup>8 9 14 30</sup> Our fully anticoagulated patients had an event rate lower than what was previously described in the literature; however, there were only four patients partitioned into this cohort.

The strength of our study was the manual extraction of data allowing for detailed determination of the type, dosage, and timing of anticoagulation/antiplatelet initiation and the timing of any acute VTE events. In addition, patients were followed 6 months after hospital discharge for any further VTE events. Regional and national databases may list injuries and complications; however, they do not have the granularity of the treatment regimen provided. There are, however, some limitations

to consider. This was a single-center study and the analysis was therefore limited. Operative interventions, VTE prophylaxis, and screening processes may not be the same at all other institutions.

In addition, with a final cohort of 26 patients, our study was underpowered to detect a statistical significance between the various cohorts. This further limited our ability to apply more rigorous excluding parameters, to perform a multivariable analysis or to stratify patients based on a number of confounding variables, as it is plausible that a selection bias exists in our fully anticoagulated patients. Furthermore, the classification scheme is not without inherent limitations. Given that group assignments were made based on the immediate last therapy, length of therapy and missed doses were not accounted for. Such a patient may have undergone a lengthy hospital course without receiving

**Table 5** Hospital day of acute thrombotic event and of anticoagulant/antiplatelet initiation

	Full (n=4)	Prophylactic+antiplatelet (n=10)	Prophylactic (n=8)	None (n=4)
First acute thrombosis hospital day	n=0	10 (4–11), n=3	5 (3–7), n=4	6 (1–11), n=2
Full hospital day initiation	3 (1–12), n=4	N/A	N/A	N/A
Prophylactic hospital day initiation	2 (1–4), n=4	3 (1–14), n=10	3 (0–3), n=8	N/A
Antiplatelet hospital day initiation	4 (2–6), n=2	3 (1–18), n=10	N/A	N/A

All values are median (IQR).  
N/A, not applicable.

antithrombotic agents or sustaining an acute VTE event and then be placed on full-dose anticoagulation in the days preceding discharge. Consequently, this patient would be classified as receiving full-dose anticoagulation.

Our study also had a high prevalence of penetrating mechanisms with a patient population that was entirely male. Of note, in general female trauma patients<sup>31–33</sup> and patients with a blunt mechanism<sup>34–36</sup> are more likely to be of the hypercoagulable phenotype than of the hyperfibrinolytic phenotype. IVC filter placement can also mitigate some risk; however, placement is not without risk.<sup>37–43</sup> As such, this is a controversial topic that needs further investigation in this population as treatment options vary widely in the literature.<sup>44–49</sup> The granularity of our data presented a unique opportunity to demonstrate that patients receiving lower doses of anticoagulation/antiplatelet medications had an overall higher incidence of VTE events, all while not having any major bleeding complications in the fully anticoagulated cohort. This outcome is applicable with the understanding that the level of evidence is insufficient.

Although there is a growing body of literature regarding coagulopathy in traumatically injured patients, there remains a paucity of data regarding trauma subpopulations that may benefit from higher doses of VTE prophylaxis, including IVC-injured patients. We think that future prospective multicenter clinical trials should capture coagulation phenotypes and anticoagulation/antiplatelet initiation practices. These details would serve to inform clinical practice guidelines as future directives decide on how to best handle traumatic IVC-injured patients. Our findings can then facilitate a more robust power analysis for a future multicenter trial.

## CONCLUSION

In this retrospective, single-center, observational study of a large, urban, academic, level 1 trauma center, we found that IVC-injured patients have a high incidence of acute VTE events. There appears to be a lower incidence of acute VTE events in patients who were prophylactically fully anticoagulated compared with patients who had other regimens of antithrombotic agents. Consideration of appropriate anticoagulation/antiplatelet initiation should ensue after hemostatic stabilization. A future prospective multicenter trial should capture the temporal characteristics of anticoagulation/antiplatelet treatment modalities to further inform clinical practice.

**Contributors** AMH, DRS, JSP, PMR, and NM designed the study. AMH, BCB, and MJS searched the literature. AMH, SM, and BCB acquired the data. AMH analyzed the data. AMH, DRS, SM, JSP, PMR, MJS, and NM participated in data interpretation. AMH and BCB drafted the article, which all authors critically revised for important intellectual content and approved the final version to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. AMH accepts full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** This study was reviewed and approved by the University of Pennsylvania Institutional Review Board (protocol number: 843994). The investigators adhered to the policies regarding the protection of human subjects as prescribed by the Code of Federal Regulations Title 45, Volume 1, Part 46; Title 32, Chapter 1, Part 219; and Title 21, Chapter 1, Part 50 (Protection of Human Subjects).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iD

Allyson M Hynes <http://orcid.org/0000-0001-8037-2290>

## REFERENCES

- Mullins RJ, Lucas CE, Ledgerwood AM. The natural history following venous ligation for civilian injuries. *J Trauma* 1980;20:737–43.
- Coimbra R, Hoyt D, Winchell R, Simons R, Fortlage D, Garcia J. The ongoing challenge of retroperitoneal vascular injuries. *Am J Surg* 1996;172:541–5.
- Tyburski JG, Wilson RF, Dente C, Steffes C, Carlin AM. Factors affecting mortality rates in patients with abdominal vascular injuries. *J Trauma* 2001;50:1020–6.
- Navsaria PH, de Bruyn P, Nicol AJ. Penetrating abdominal vena cava injuries. *Eur J Vasc Endovasc Surg* 2005;30:499–503.
- Huerta S, Bui TD, Nguyen TH, Banimahd FN, Porral D, Dolich MO. Predictors of mortality and management of patients with traumatic inferior vena cava injuries. *Am Surg* 2006;72:290–6.
- Paul JS, Webb TP, Aprahamian C, Weigelt JA. Intraabdominal vascular injury: are we getting any better? *J Trauma* 2010;69:1393–7.
- Sullivan PS, Dente CJ, Patel S, Carmichael M, Srinivasan JK, Wyrzykowski AD, Nicholas JM, Salomone JP, Ingram WL, Verucryse GA, et al. Outcome of ligation of the inferior vena cava in the modern era. *Am J Surg* 2010;199:500–6.
- Singer MB, Hadjibashi AA, Bukur M, Ley EJ, Mirocha J, Malinoski DJ, Margulies DR, Salim A. Incidence of venous thromboembolism after inferior vena cava injury. *J Surg Res* 2012;177:306–9.
- Matsumoto S, Jung K, Smith A, Coimbra R. Management of IVC injury: repair or ligation? A propensity score matching analysis using the National trauma data bank. *J Am Coll Surg* 2018;226:752–9.
- Klein SR, Baumgartner FJ, Bongard FS. Contemporary management strategy for major inferior vena caval injuries. *J Trauma* 1994;37:35–42.
- Burch JM, Feliciano DV, Mattox KL, Edelman M. Injuries of the inferior vena cava. *Am J Surg* 1988;156:548–52.
- DuBose JJ, Savage SA, Fabian TC, Menaker J, Scalea T, Holcomb JB, Skarupa D, Poulin N, Chourliaras K, Inaba K, et al. The American association for the surgery of trauma prospective observational vascular injury treatment (PROOVIT) registry: multicenter data on modern vascular injury diagnosis, management, and outcomes. *J Trauma Acute Care Surg* 2015;78:215–22.
- Buckman RF, Pathak AS, Badellino MM, Bradley KM. Injuries of the inferior vena cava. *Surg Clin North Am* 2001;81:1431–47.
- Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. *N Engl J Med* 1994;331:1601–6.
- Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, et al. The coagulopathy of trauma: a review of mechanisms. *J Trauma* 2008;65:748–54.
- Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. *Arterioscler Thromb Vasc Biol* 1998;18:677–85.
- Berk BC, Abe JI, Min W, Surapisitthachit J, Yan C. Endothelial atheroprotective and anti-inflammatory mechanisms. *Ann N Y Acad Sci* 2001;947:93–111.
- Mammen EF. Pathogenesis of venous thrombosis. *Chest* 1992;102:640S–4.
- Chiu J-J, Chien S. Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. *Physiol Rev* 2011;91:327–87.
- Lozano LMB, Perel P, Ker K, Cirocchi R, Farinella E, Morales CH. Thromboprophylaxis for trauma patients. *Cochrane Database Syst Rev* 2010;2010.
- Velmahos GC, Kern J, Chan LS, Oder D, Murray JA, Shekelle P. Prevention of venous thromboembolism after injury: an evidence-based report-part 1: analysis of risk factors and evaluation of the role of vena caval filters. *J Traumadiscussion* 2000;49:132–8.
- Frank B, Maher Z, Hazelton JP, Resnick S, Dauer E, Goldenberg A, Lubitz AL, Smith BP, Saillant NN, Reilly PM, et al. Venous thromboembolism after major venous injuries: competing priorities. *J Trauma* 2017;83:1095–101.
- Shackford SR, Davis JW, Hollingsworth-Fridlund P, Brewer NS, Hoyt DB, Mackersie RC. Venous thromboembolism in patients with major trauma. *Am J Surg* 1990;159:365–9.

- 24 Brill JB, Badiee J, Zander AL, Wallace JD, Lewis PR, Sise MJ, Bansal V, Shackford SR. The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography. *J Trauma Acute Care Surg* 2017;83:413–9.
- 25 Louis SG, Sato M, Geraci T, Anderson R, Cho SD, Van PY, Barton JS, Riha GM, Underwood S, Differding J, *et al*. Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. *JAMA Surg* 2014;149:365–70.
- 26 Knudson MM, Collins JA, Goodman SB, McCrory DW. Thromboembolism following multiple trauma. *J Trauma* 1992;32:2–11.
- 27 Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. *J Trauma* 1994;37:480–7.
- 28 Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of surgeons national trauma data bank. *Ann Surg* 2004;240:490–6.
- 29 Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration. *BMJ* 1994;308:235–46.
- 30 Degiannis E, Velmahos GC, Levy RD, Souter I, Benn CA, Saadia R. Penetrating injuries of the abdominal inferior vena cava. *Ann R Coll Surg Engl* 1996;78:485–9.
- 31 Gorton HJ, Warren ER, Simpson NA, Lyons GR, Columb MO. Thromboelastography identifies sex-related differences in coagulation. *Anesth Analg* 2000;91:1279–81.
- 32 Schreiber MA, Differding J, Thorborg P, Mayberry JC, Mullins RJ. Hypercoagulability is most prevalent early after injury and in female patients. *J Trauma* 2005;58:475–81.
- 33 Coleman JR, Moore EE, Samuels JM, Cohen MJ, Sauaia A, Sumislawski JJ, Ghasabyan A, Chandler JG, Banerjee A, Silliman CC, *et al*. Trauma resuscitation consideration: sex matters. *J Am Coll Surg* 2019;228:760–8.
- 34 Meizoso JP, Karcutskie CA, Ray JJ, Namias N, Schulman CI, Proctor KG. Persistent fibrinolysis shutdown is associated with increased mortality in severely injured trauma patients. *J Am Coll Surg* 2017;224:575–82.
- 35 Moore HB, Moore EE, Liras IN, Gonzalez E, Harvin JA, Holcomb JB, Sauaia A, Cotton BA. Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients. *J Am Coll Surg* 2016;222:347–55.
- 36 Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. *J Trauma* 1997;42:716–22. discussion 720–2.
- 37 Vijay K, Hughes JA, Burdette AS, Scorza LB, Singh H, Waybill PN, Lynch FC, Recovery FB. Fractured bard recovery, G2, and G2 express inferior vena cava filters: incidence, clinical consequences, and outcomes of removal attempts. *J Vasc Interv Radiol* 2012;23:188–94.
- 38 Durack JC, Westphalen AC, Kekulawela S, Bhanu SB, Avrin DE, Gordon RL, Kerlan RK. Perforation of the IVC: rule rather than exception after longer indwelling times for the Günther tulip and Celect retrievable filters. *Cardiovasc Intervent Radiol* 2012;35:299–308.
- 39 Sarosiek S, Rybin D, Weinberg J, Burke PA, Kasotakis G, Sloan JM. Association between inferior vena cava filter insertion in trauma patients and in-hospital and overall mortality. *JAMA Surg* 2017;152:75–81.
- 40 Go MR, Keller-Biehl L, Starr JE. Penetration of the inferior vena cava and adjacent organs after filter placement is associated with retrievable filter type and length of time in place. *J Vasc Surg Venous Lymphat Disord* 2014;2:174–8.
- 41 Teo TKB, Angle JF, Shipp JJ, Bluett MK, Gilliland CA, Turba UC, Matsumoto AH. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ED: American College of chest physicians evidence-based clinical practice guidelines. *Chest* 2012;141:e227S.
- 42 Teo TKB, Angle JF, Shipp JJ, Bluett MK, Gilliland CA, Turba UC, Matsumoto AH. Incidence and management of inferior vena cava filter thrombus detected at time of filter retrieval. *J Vasc Interv Radiol* 2011;22:1514–20.
- 43 Andreoli JM, Lewandowski RJ, Vogelzang RL, Ryu RK. Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database. *J Vasc Interv Radiol* 2014;25:1181–5.
- 44 Ley EJ, Brown CVR, Moore EE, Sava JA, Peck K, Ciesla DJ, Sperry JL, Rizzo AG, Rosen NG, Brasel KJ, *et al*. Updated guidelines to reduce venous thromboembolism in trauma patients: a Western trauma association critical decisions algorithm. *J Trauma Acute Care Surg* 2020;89:971–81.
- 45 Haut ER, Garcia LJ, Shihab HM, Brotman DJ, Stevens KA, Sharma R, Chelladurai Y, Akande TO, Shermock KM, Kebede S, *et al*. The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. *JAMA Surg* 2014;149:194–202.
- 46 Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of chest physicians evidence-based clinical practice guidelines (8th edition). *Chest* 2008;133:381S–453.
- 47 Kelkar AH, Rajasekhar A. Inferior vena cava filters: a framework for evidence-based use. *Hematology Am Soc Hematol Educ Program* 2020;2020:619–28.
- 48 Spahn DR, Bouillon B, Cerny V, Duranteau J, Filipescu D, Hunt BJ, Komadina R, Maegele M, Nardi G, Riddez L, *et al*. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. *Crit Care* 2019;23:98.
- 49 Rappold JF, Sheppard FR, Carmichael II SP, Cuschieri J, Ley E, Rangel E, Seshadri AJ, Michetti CP. Venous thromboembolism prophylaxis in the trauma intensive care unit: an American association for the surgery of trauma critical care Committee clinical consensus document. *Trauma Surg Acute Care Open* 2021;6:e000643.

---

**SUPPLEMENTAL TABLE 1.** Examples of Duplex Screening Protocol Risk Categories.
 

---

**2008-2012**

## High-risk

Age >50  
 Injury Severity Score  $\geq$  16  
 Femoral central venous catheter in trauma resuscitation  
 AIS  $\geq$  3 (any body region)  
 GCS < 9  
 Pelvic Fracture  
 Femur/tibia fracture  
 Venous injury

## Very high-risk

Spinal cord injury  
 AIS (head and neck)  $\geq$  3 & long bone fracture (upper or lower)  
 Severe pelvic fracture (posterior element), and long bone fracture (upper or lower)  
 Multiple ( $\geq$  3) long bone fracture

---

**2017**

## Very high-risk

Spinal cord injury or paralysis  
 Severe traumatic brain injury  
 Stroke  
 Posterior pelvis + long bone fracture  
 $\geq$  3 long bone fractures  
 History of venous thromboembolism event

---

 AIS, Abbreviated Injury Scale; GCS, Glasgow Coma Scale
 

---

**SUPPLEMENTAL TABLE 2.** Description of Bleeding Events During Hospitalization.

Pt	Description of the Bleeding Event
1	HD 22,23 embolization proximal branch SMA OSHx2, HD 31 CRRT catheter removed, bled, transfused 3PRBC, 2FFP, DDAVP, HD 47 Large bilateral STSG donor sights oozy 4PRBC, 2 FFP, DDAVP+ 2 more overnight
2	Pt on prophylaxis (earlier had been on ASA) HD 14 received 2 units of PRBCs and DDAVP for bloody JP output (CTA-). HD 25 received 1 unit of PRBC for Hgb 6.8
3	Heparin gtt since HD 1. HD 6 held heparin gtt until HD 10 for hemoglobin drifting from HD 3 from a hemoglobin of 9. HD 4 to 6, initiated prophylaxis & Aspirin 325. Received 1 unit total
6	Prophylactic and ASA pt. Lumbar a coiled & psa artery embolization. HD 2 received 1 unit then intraoperatively during orthopedic bilateral ORIF received 2 units
9	HD 10 received 2 units of PRBCs. HD 21 2 units PRBCs. HD 27 2 units of PRBCs. HD 39 Marginal ulcer diagnosed. HD 48 2 units PRBCs. HD 54 2 units for diffuse bleeding from abdominal wound. HD 85 DDAVP and 2 units of PRBCs. HD 96 1 units of PRBCs.
11	Gastrointestinal bleeding resulting in less than two units of product being transfused
16	On HD 21 repeat ERCP with repositioning of stent. Upon removal of stent bleeding noted. Went to IR for embolization of GDA.
20	Contemplating Heparin gtt on HD 2 however blood tinge output from PCN. Required 2u for Hgb of 6.9 on HD 3. Heparin gtt initiated HD 5 with the DVT then HD 8 2 units from bleeding from incision and HD 9-10 3 units for incisional bleeding (Heparin gtt held on HD 9). Filter obtained HD 10
24	HD 15 1u PRBCs while on Heparin gtt for a hemoglobin of 6.9
26	IVC-F patient who was on the floor. He had been on the Heparin gtt for HD 14-29 & developed a gastrointestinal bleed requiring one unit, full dose AC discontinued

A, Artery; AC, Anticoagulation; ASA, Aspirin; CRRT, Continuous Renal Replacement Therapy; CTA, computed tomography angiography; DDAVP, Desmopressin; ERCP, Endoscopic Retrograde Cholangiopancreatography; FFP, Fresh Frozen Plasma; GDA, Gastroduodenal Artery; GTT, drip; HD, Hospital Day; Hgb, Hemoglobin; IVC-F, Inferior Vena Cava Filter; IR, Interventional Radiology; JP, Jackson-Pratt Drain; ORIF, Open Reduction and Internal Fixation; OSH, Outside Hospital; PCN, Percutaneous Nephrostomy; PRBC, Packed Red Blood Cell; PSA, Posterior Superior Alveolar; Pt, Patient; SMA, Superior Mesenteric Artery; STSG, Split Thickness Skin Graft

**SUPPLEMENTAL TABLE 3. Discharge Antithrombotic Regimens by Venous Thromboembolism Status.**

Pt	VTE	Discharge Antithrombotic Regimen
1	N/A	Aspirin 81 mg daily (IVC filter patient)
2	N/A	Aspirin 81 mg daily
3	N/A	Apixaban completed 10 mg twice daily load followed by 5 mg twice daily
4	N/A	None
5	N/A	Dabigatran 150 mg twice daily
6	N/A	Aspirin 81 mg daily and Effient 10 mg daily (home medications)
7	N/A	Aspirin 81 mg daily
8	N/A	None
9	N/A	Heparin 5000 units three times daily
10	N/A	Aspirin 325 mg daily
11	N/A	None
12	N/A	Aspirin 325 mg daily
13	N/A	None
14	N/A	None
15	N/A	None
16	N/A	Aspirin 325 mg daily
17	DVT	Rivaroxaban completed 15 mg twice daily load followed by 20 mg once daily
18	N/A	Enoxaparin 100 mg daily
19	DVT & PE	Enoxaparin 120 mg twice daily
20	DVT	None (IVC filter patient)
21	PE	Apixaban 10 mg twice daily load followed by 5 mg twice daily
22	DVT	None (IVC filter patient)
23	DVT & PE	Enoxaparin 100 mg twice daily bridge with Coumadin 7.5 mg (IVC filter patient, removed during the same admission)
24	DVT	Coumadin 2.5 mg daily
25	DVT	Coumadin 7.5 mg daily with Aspirin 81 mg daily
26	DVT & PE	None (IVC filter patient, who required one unit of blood on the floor for a gastrointestinal bleed that resulted in stopping the antithrombotic agents)

DVT, Deep Venous Thrombosis; IVC, Inferior Vena Cava; mg, milligrams; N/A, Not Applicable; PE, Pulmonary Embolism; PT, Patient; VTE, Venous Thromboembolism

## STROBE Statement—checklist of items that should be included in reports of observational studies

	<b>Item No.</b>	<b>Recommendation</b>	<b>Page No.</b>	<b>Relevant text from manuscript</b>
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Title Pg	The Role of Anticoagulants and Antiplatelets in IVC Injuries
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract	See abstract
<b>Introduction</b>				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Pg. 2-3	Introduction Section
Objectives	3	State specific objectives, including any prespecified hypotheses	Pg. 3	We conducted a retrospective clinical study in which our hypothesis was that varied anticoagulant & antiplatelet dose regimens exist, and these regimens will result in a varied incidence of acute VTE events following IVC injury.
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	Pg. 3-4 Patient and Data Collection	See item below (item #5)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Pg. 3-4 Patient and Data Collection	We performed a retrospective observational study at our large, urban, academic, medical center and level 1 trauma center between January 1st, 2008 and December 31st, 2020. Data was curated from our institutional trauma registry and electronic medical record (EMR). The registry was queried for all patients who sustained a traumatic IVC injury requiring hospital admission. Upon EMR review, patients who were ultimately found not to have sustained an IVC injury or if they died within the index 72 hours were excluded from analysis.

An investigation of cause of death was performed on the patients who survived beyond their index operation; however, succumbed to death within the first 72 hours. Furthermore, due to the inherent differences in underline presenting physiology, a patient was excluded from the VTE analysis if they underwent an IVC ligation (Supplemental Figure 1).

We classified patients into four cohorts: full dose anticoagulation, prophylactic dose anticoagulation, prophylactic dose anticoagulation with concomitant antiplatelet agent, and no anticoagulant or antiplatelet agent. During the study period, standard of care prophylaxis was based on empiric dosing and not titrated to any measure. Patients were assigned to their cohort depending on their current treatment before an acute VTE event or hospital discharge, whichever occurred first. Therefore, if a patient received full dose anticoagulation, then the patient transitioned to prophylactic anticoagulation before they sustained an acute VTE, the patient was analyzed in the prophylactic dose regimen. Preexisting home medications were characterized. Our analysis included any available EMR data up to six months post-acute hospitalization discharge.

Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case	Pg 3-4 Patient and Data	The registry was queried for all patients who sustained a traumatic IVC injury requiring hospital
--------------	---	--	-------------------------------	---

		ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	Collection	admission. Upon EMR review, patients who were ultimately found not to have sustained an IVC injury or if they died within the index 72 hours were excluded from analysis. An investigation of cause of death was performed on the patients who survived beyond their index operation; however, succumbed to death within the first 72 hours. Furthermore, due to the inherent differences in underline presenting physiology, a patient was excluded from the VTE analysis if they underwent an IVC ligation (Supplemental Figure 1); Our analysis included any available EMR data up to six months post-acute hospitalization discharge.
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Pg. 4 For exposures	We classified patients into four cohorts: full dose anticoagulation, prophylactic dose anticoagulation, prophylactic dose anticoagulation with concomitant antiplatelet agent, and no anticoagulant or antiplatelet agent. During the study period, standard of care prophylaxis was based on empiric dosing and not titrated to any measure. Patients were assigned to their cohort depending on their current treatment before an acute VTE event or hospital discharge, whichever occurred first.
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Pg 4	See item #6 additionally- Our primary outcome was the incidence of an acute VTE event. An acute VTE included: IVC thrombus (presumed at site of injury), any DVT distal to the IVC injury (i.e. ileac veins), or PE. Only a

				patient's first acute VTE event was recorded in the analysis for time to VTE event. If a patient sustained both a DVT and a PE this was also characterized.
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Pg. 3	Data was curated from our institutional trauma registry and electronic medical record (EMR).
Bias	9	Describe any efforts to address potential sources of bias	Pg. 10-11 of Discussion Section	<p>Limitations sections of discussion, This was a single-center study, and the analysis was therefore limited. Operative interventions, VTE prophylaxis, and screening processes may not be the same at all other institutions.</p> <p>In addition, with a final cohort of 26 patients, our study was underpowered to detect a statistical significance between the various cohorts. This further limited our ability to apply more rigorous excluding parameters, to perform a multivariable analysis or to stratify patients based on a number of confounding variables, as it is plausible that a selection bias exists in our fully anticoagulated patients. Furthermore, the classification scheme is not without inherent limitations. Given that group assignments were made based on the immediate last therapy, length of therapy and missed doses were not accounted for. Such as a patient may have undergone a lengthy hospital course without receiving antithrombotic agents or sustaining an acute VTE event, and then be placed on full dose anticoagulation in the days</p>

---

preceding discharge.  
Consequently, this patient would be classified as receiving full dose anticoagulation.

Our study also had a high prevalence of penetrating mechanisms with a patient population that was entirely male. Of note, in general female<sup>31–33</sup> trauma patients and patients with a blunt<sup>34–36</sup> mechanism are more likely to be of the hypercoagulable phenotype than of the hyperfibrinolytic phenotype.

(Supplemental Figure 1).

---

Study size 10 Explain how the study size was arrived at

Pg. 4

Continued on next page

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A	N/A. Statistics removed. Continuous variables were reported with median sd
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	N/A	See # 11 and #14
		(b) Describe any methods used to examine subgroups and interactions	N/A	N/A
		€ Explain how missing data were addressed	Pg. 6	Data was missing on four (15.4%) of the patients' home medications. However, none of these four patients had a preexisting condition warranting an antithrombotic agent.
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed Case-control study—If applicable, explain how matching of cases and controls was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	Pg. 8 of Results	Finally, one patient (3.8%) did not complete post-hospitalization follow-up.
		€ Describe any sensitivity analyses	Pg 4, 8	An investigation of cause of death was performed on the patients who survived beyond their index operation; however, succumbed to death within the first 72 hours; Of the four patients who died within the index 72 hours, one died immediately after their operation and the remainder had a re-exploratory laparotomy confirming coagulopathy as the cause of death.
<b>Results</b>				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Pg. 5-6	Of the 84 patients screened from the registry query, 76 sustained an IVC injury upon EMR review. 26 patients met all the inclusion and exclusion criteria. On EMR review, eight were excluded as they did not have an IVC injury, 23 patients died in the emergency department, 22 died in the operating room and four died within the index 72 hours (Supplemental Figure 1). In addition, one patient underwent an IVC ligation.

				Four patients were partitioned into the therapeutic dose anticoagulation. Ten patients received concomitant prophylactic dose anticoagulation and antiplatelet agent. Nine patients received prophylactic dose anticoagulation. Four patients did not receive any anticoagulation or antiplatelet agents. Of the fully anticoagulated patients, two received a concomitant antiplatelet agent during part of their hospital course..And see Supplemental Figure 1 and #12
		(b) Give reasons for non-participation at each stage	Pg. 8	Loss of post-hospitalization follow-up noted above (item #12)
		(c) Consider use of a flow diagram	Supplemental	Supplemental Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Tables, Pg. 6	See tables, Overall, 26 (100.0 %) were male and the median age was 26 (interquartile range [IQR] 16 to 51). Twenty-four (92.3%) patients sustained a penetrating injury. Twenty-two (84.6%) patients sustained a gunshot wound and descriptors of their injury burden and operative details are listed in Table 1, including 24 (92.3 %) who went to the operating theatre. These 26 patients were admitted by 18 different trauma attendings. Table 2 depicts the patients' injuries, including their cava injuries. None of the patients were noted to be on an anticoagulant as a home medication; however, one patient in the prophylactic anticoagulation with a concomitant antiplatelet agent was noted to have aspirin and effient as home medications. Data

				was missing on four (15.4%) of the patients' home medications. However, none of these four patients had a preexisting condition warranting an antithrombotic agent.
		(b) Indicate number of participants with missing data for each variable of interest	(Methods) Pg. 6,8	Loss of post-hospitalization follow-up noted above (item #12) and missing data also noted in item #12
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Pg. 4; Pg. 8	Our analysis included any available EMR data up to six months post-acute hospitalization discharge; Finally, one patient (3.8%) did not complete post-hospitalization follow-up.
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Pg. 6-8 Tables	Reported overall incidence (pg 6-8)
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	N/A	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A	N/A
		(b) Report category boundaries when continuous variables were categorized	Pg. 6, 7 and Tables	Overall, 26 (100.0 %) were male and the median age was 26 (interquartile range [IQR] 16 to 51); The median day to onset of an acute VTE event was five (interquartile range [IQR] 1 to 11). And tables
		© If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	N/A

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	N/A
<b>Discussion</b>				
Key results	18	Summarise key results with reference to study objectives	Pg. 8-9	Traumatically injured patients often have risk factors that lend them to be hypercoagulable, rendering them susceptible to VTE events. <sup>14,15</sup> In this retrospective study of IVC injured patients, we sought to determine the association between anticoagulation / antiplatelet status and the incidence of acute VTE events. Our results show this group to be very high risk with a 50.0% acute VTE event rate in the patients with prophylactic dose anticoagulation and in the patients who were not receiving an antithrombotic agent. On the other hand, those receiving full dose anticoagulation had a 0.0% acute VTE event rate. These novel and striking findings, should prompt the reader to consider more aggressive anticoagulation / antiplatelet treatment therapies in this high-risk population.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pg. 10-11	Limitation Paragraphs
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pg. 11	The granularity of our data presented a unique opportunity to demonstrate that the patients receiving lower doses of anticoagulation / antiplatelet medications had an overall higher incidence of VTE events, all while not having any major bleeding complications in the fully anticoagulated cohort. This outcome is applicable with the understanding that the level of evidence is insufficient.

Generalisability	21	Discuss the generalisability (external validity) of the study results	Pg. 11	Our study also had a high prevalence of penetrating mechanisms with a patient population that was entirely male. Of note, in general female <sup>31–33</sup> trauma patients and patients with a blunt <sup>34–36</sup> mechanism are more likely to be of the hypercoagulable phenotype than of the hyperfibrinolytic phenotype.
<b>Other information</b>				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Pg. 12	Funding: None.

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

## Supplemental Figure 1

